Innovation in Tuberculosis

Summary

Tuberculosis (TB) is one of the major infectious diseases worldwide, and the emergence and spread of drug resistant cases is a public health threat. However, the conventional methods used for diagnosis and drug-susceptibility testing are not enough for controlling the disease. In addition, all TB patients, independently of their age, gender, severity of the disease and type of responsible strain, follow the same treatment duration (up to 20 months in drug resistant cases), which often leads to high frequency of adverse events, suboptimal adherence to treatment, and poor outcome. Therefore, a transition from programmatic to personalized management of TB is needed.

INNOVA4TB proposal will develop innovative technologies and approaches in order to improve the individual risk assessment for TB development, to rapidly diagnose active TB, to detect the drug susceptibility of the strain, to design tailor-made therapies, and to use biomarkers to guide and individualize the duration of antimicrobial therapy. This is of great importance for improving the quality of life of patients and ensuring treatment success, as well as for economic reasons for the healthcare system.

Conditions

• Tuberculosis

Interventions

DIAGNOSTIC_TEST

Immunologic, molecular, metabolomic and radiolologic diagnostic

Evaluation and development of new technologies

Sponsors & Collaborators

• Consorcio Centro de Investigación Biomédica en Red (CIBER)

  collaborator OTHER_GOV

• Umeå University

  collaborator OTHER

• North-Western State Medical University named after I.I.Mechnikov

  collaborator OTHER

• INSTITUTUL DE FTIZIOPNEUMOLOGIE CHIRIL DRAGANIUC

  collaborator UNKNOWN

• ODESA SIGNIFICANT DISEASES CENTER

  collaborator UNKNOWN

• Vinnitsa National Medical University

  collaborator OTHER

• SERVICIOS CLINICOS SA

  collaborator UNKNOWN

• Genome Identification Diagnostics GmbH

  collaborator UNKNOWN

• EMPE DIAGNOSTICS AB

  collaborator UNKNOWN

• MAGRITEK GMBH

  collaborator UNKNOWN

• Universidad de La Frontera

  collaborator OTHER

• Fundació Institut Germans Trias i Pujol

  lead OTHER

Eligibility

Min Age

1 Month

Max Age

99 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2019-01-01

Primary Completion

2021-12-31

Completion

2022-12-31

Countries

• Spain

Study Locations